1887
  1. Home
  2. Eurosurveillance
  3. Volume 26, Issue 25, 24/Jun/2021
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

To assess the real-world impact of vaccines on COVID-19 related outcomes, we analysed data from over 7 million recipients of at least one COVID-19 vaccine dose in Italy. Taking 0–14 days post-first dose as reference, the SARS-CoV-2 infection risk subsequently decreased, reaching a reduction by 78% (incidence rate ratios (IRR): 0.22; 95% CI: 0.21–0.24) 43–49 days post-first dose. Similarly, hospitalisation and death risks decreased, with 89% (IRR: 0.11; 95% CI: 0.09–0.15) and 93% (IRR: 0.07; 95% CI: 0.04–0.11) reductions 36–42 days post-first dose. Our results support ongoing vaccination campaigns.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.25.2100507
2021-06-24
2024-11-21
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2021.26.25.2100507
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/25/eurosurv-26-25-1.html?itemId=/content/10.2807/1560-7917.ES.2021.26.25.2100507&mimeType=html&fmt=ahah

References

  1. Agenzia Italiana del Farmaco (AIFA). Vaccini COVID-19. Rome: AIFA. [COVID-19 Vaccines]. [Accessed 19 May 2021]. Available from: https://www.aifa.gov.it/vaccini-covid-19
  2. Ministero della Salute. Piano strategico per la vaccinazione anti-SARS-CoV-2/COVID-19. [Strategic plan for SARS-CoV-2 / COVID-19 vaccination]. Rome: Ministero della Salute; 2020. Italian. Available from: https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2021&codLeg=78657&parte=1&serie=null
  3. Riccardo F, Ajelli M, Andrianou XD, Bella A, Del Manso M, Fabiani M, et al. , COVID-19 working group. Epidemiological characteristics of COVID-19 cases and estimates of the reproductive numbers 1 month into the epidemic, Italy, 28 January to 31 March 2020. Euro Surveill. 2020;25(49):2000790. . Available from: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.49.2000790 https://doi.org/10.2807/1560-7917.ES.2020.25.49.2000790  PMID: 33303064 
  4. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. , C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.  https://doi.org/10.1056/NEJMoa2034577  PMID: 33301246 
  5. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. , COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-16.  https://doi.org/10.1056/NEJMoa2035389  PMID: 33378609 
  6. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. , Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.  https://doi.org/10.1016/S0140-6736(20)32661-1  PMID: 33306989 
  7. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021;384(15):1412-23.  https://doi.org/10.1056/NEJMoa2101765  PMID: 33626250 
  8. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. , SIREN Study Group. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021;397(10286):1725-35.  https://doi.org/10.1016/S0140-6736(21)00790-X  PMID: 33901423 
  9. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819-29.  https://doi.org/10.1016/S0140-6736(21)00947-8  PMID: 33964222 
  10. Fabiani M, Ramigni M, Gobbetto V, Mateo-Urdiales A, Pezzotti P, Piovesan C. Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021. Euro Surveill. 2021;26(17):2100420.  https://doi.org/10.2807/1560-7917.ES.2021.26.17.2100420  PMID: 33928898 
  11. Tenforde MW, Olson SM, Self WH, Talbot HK, Lindsell CJ, Steingrub JS, et al. , IVY Network, HAIVEN Investigators. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):674-9.  https://doi.org/10.15585/mmwr.mm7018e1  PMID: 33956782 
  12. Vasileiou E, Simpson CR, Robertson C, Shi T, Kerr S, Agrawal U, et al. Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People. SSRN Electron J. 2021. [Accessed 4 May 2021].  https://doi.org/10.2139/ssrn.3789264 
  13. Day M. Covid-19: Stronger warnings are needed to curb socialising after vaccination, say doctors. BMJ. 2021;372(783):n783.  https://doi.org/10.1136/bmj.n783  PMID: 33741565 
Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Alberto++Mateo-Urdiales&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mateo-Urdiales Alberto </a>, <a href="/search?value1=Stefania++Spila+Alegiani&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Spila Alegiani Stefania </a>, <a href="/search?value1=Massimo+Fabiani&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fabiani Massimo</a>, <a href="/search?value1=Patrizio+Pezzotti&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pezzotti Patrizio</a>, <a href="/search?value1=Antonietta+Filia&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Filia Antonietta</a>, <a href="/search?value1=Marco+Massari&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Massari Marco</a>, <a href="/search?value1=Flavia+Riccardo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Riccardo Flavia</a>, <a href="/search?value1=Marco+Tallon&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Tallon Marco</a>, <a href="/search?value1=Valeria+Proietti&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Proietti Valeria</a>, <a href="/search?value1=Martina+Del+Manso&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Del Manso Martina</a>, <a href="/search?value1=Maria+Puopolo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Puopolo Maria</a>, <a href="/search?value1=Matteo+Spuri&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Spuri Matteo</a>, <a href="/search?value1=Cristina+Morciano&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Morciano Cristina</a>, <a href="/search?value1=Fortunato+%28Paolo%29+D%E2%80%99Ancona&option1=author&noRedirect=true" class="nonDisambigAuthorLink">D’Ancona Fortunato (Paolo)</a>, <a href="/search?value1=Roberto+Da+Cas&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Da Cas Roberto</a>, <a href="/search?value1=Serena+Battilomo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Battilomo Serena</a>, <a href="/search?value1=Antonino+Bella&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bella Antonino</a>, <a href="/search?value1=Francesca+Menniti-Ippolito&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Menniti-Ippolito Francesca</a>, <a href="/search?value1=on+behalf+of+the+Italian+Integrated+Surveillance+of+COVID-19+study+group&option1=author&noRedirect=true" class="nonDisambigAuthorLink">on behalf of the Italian Integrated Surveillance of COVID-19 study group</a>, <a href="/search?value1=on+behalf+of+the+Italian+COVID-19+vaccines+registry&option1=author&noRedirect=true" class="nonDisambigAuthorLink"> on behalf of the Italian COVID-19 vaccines registry</a></span>. Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021. <a href="/content/ecdc">Euro Surveill.</a> 2021;26(25):pii=2100507. <a href="https://doi.org/10.2807/1560-7917.ES.2021.26.25.2100507" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2021.26.25.2100507</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 24 May 2021;&nbsp;&nbsp; <span class="generated">Accepted</span>: 24 Jun 2021 </span> </p>
/content/10.2807/1560-7917.ES.2021.26.25.2100507
/content/10.2807/1560-7917.ES.2021.26.25.2100507
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error